Recro Pharma/SCTL

$0.54

6.48%
-
1D1W1MYTD1YMAX

About Recro Pharma

Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus on the area of small molecules. It is involved in CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company’s products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR, Donnatal liquids and tablets and Scot-Tussin cough and cold liquids. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms and facilities to handle highly potent compounds and controlled substances.

Ticker

SCTL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

J. David Enloe

Employees

275

Headquarters

Exton, United States

Recro Pharma Metrics

BasicAdvanced
$53.13M
Market cap
-
P/E ratio
-$0.29
EPS
1.18
Beta
-
Dividend rate

What the Analysts think about Recro Pharma

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
285.19% upside
High $4.00
Low $1.00
$0.54
Current price
$2.08
Average price target

Recro Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-19.14% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$23.5M
8.29%
Net income
$-4.5M
40.63%
Profit margin
-19.14%
29.85%

Recro Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 150%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.15
-$0.06
-$0.04
-$0.05
-
Expected
-$0.07
-$0.05
-$0.03
-$0.02
-$0.01
Surprise
106.9%
20%
20%
150%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Recro Pharma stock

Buy or sell Recro Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing